Cornell University researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both COVID-19 and influenza, and broader immunity to different flu ...

Researchers indicated that while current vaccines for SARS-CoV-2 and influenza are generally safe and effective, there is still considerable room for improvement.

Researchers have discovered a virus that could enter human cells in a similar way to COVID-19. But they caution it's much ...

Department of Health and Human Services Secretary Robert F. Kennedy Jr. paused a $240 million contract to create a new coronavirus vaccine.

Emerging tools enable more accurate antigen production and presentation using mRNA instead of protein. In recent years, mRNA technology has come into its own, most prominently in the field of vaccine ...

Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...

“Findings in this report show that vaccination with the 2024–2025 influenza vaccine reduced the likelihood of medically attended influenza and support CDC’s recommendation that all persons aged ≥6 ...

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...

Scientists explored the differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccines, and other viral ...

When COVID-19 vaccines rolled out, public health officials largely followed a simple logic: protect the most vulnerable first ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, ...